FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.63, for a total value of $2,185,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

K Peony Yu also recently made the following trade(s):

  • On Thursday, September 14th, K Peony Yu sold 2,851 shares of FibroGen stock. The shares were sold at an average price of $51.00, for a total value of $145,401.00.
  • On Monday, August 21st, K Peony Yu sold 7,500 shares of FibroGen stock. The shares were sold at an average price of $41.03, for a total value of $307,725.00.
  • On Tuesday, August 8th, K Peony Yu sold 37,500 shares of FibroGen stock. The shares were sold at an average price of $50.58, for a total value of $1,896,750.00.
  • On Tuesday, August 1st, K Peony Yu sold 10,000 shares of FibroGen stock. The shares were sold at an average price of $33.48, for a total value of $334,800.00.
  • On Monday, July 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The shares were sold at an average price of $32.98, for a total value of $164,900.00.

FibroGen, Inc (NASDAQ:FGEN) traded up 7.23% during midday trading on Wednesday, hitting $60.10. The company’s stock had a trading volume of 2,814,138 shares. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $60.15. The company’s 50 day moving average price is $48.38 and its 200 day moving average price is $34.57. The firm’s market cap is $4.28 billion.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The company had revenue of $29.00 million during the quarter, compared to the consensus estimate of $34.80 million. Analysts expect that FibroGen, Inc will post ($1.80) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/04/fibrogen-inc-fgen-insider-sells-2185200-00-in-stock.html.

Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. bought a new stake in shares of FibroGen during the 1st quarter valued at $111,000. Quantbot Technologies LP bought a new stake in shares of FibroGen during the 2nd quarter valued at $128,000. SG Americas Securities LLC grew its position in shares of FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 412 shares during the period. Amalgamated Bank bought a new stake in shares of FibroGen during the 2nd quarter valued at $237,000. Finally, BNP Paribas Arbitrage SA grew its position in shares of FibroGen by 589.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after acquiring an additional 6,327 shares during the period. 47.49% of the stock is owned by hedge funds and other institutional investors.

FGEN has been the topic of several research analyst reports. Goldman Sachs Group, Inc. (The) downgraded FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. Jefferies Group LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research note on Tuesday, September 12th. BidaskClub upgraded FibroGen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. William Blair reiterated an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $48.00 price objective on shares of FibroGen in a research note on Monday, June 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $60.17.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.